Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
10:40am, Friday, 12'th Sep 2025
Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
02:21pm, Wednesday, 10'th Sep 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN). Such investors are ad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
03:00pm, Monday, 08'th Sep 2025
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN).
Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?
10:56am, Thursday, 28'th Aug 2025
The mean of analysts' price targets for AxoGen (AXGN) points to a 53.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
06:40am, Monday, 25'th Aug 2025
ALACHUA, Fla. and TAMPA, Fla.
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know
10:55am, Tuesday, 12'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positiv
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined
05:17am, Tuesday, 12'th Aug 2025
Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into th
Axogen (AXGN) Q2 Revenue Jumps 18%
06:43pm, Tuesday, 05'th Aug 2025
Axogen (AXGN) Q2 Revenue Jumps 18%
Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript
01:15pm, Tuesday, 05'th Aug 2025
Axogen, Inc. (NASDAQ:AXGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Mich
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates
09:16am, Tuesday, 05'th Aug 2025
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.05 per share a year ago.
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
04:10pm, Tuesday, 29'th Jul 2025
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 29'th Jul 2025
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
04:05pm, Tuesday, 22'nd Jul 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
08:00am, Wednesday, 28'th May 2025
ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 21'st May 2025
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
